Companies › Kura Oncology
2 active drug programs in 13 registered trials: 12 Phase 1, 1 Phase 3; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Ziftomenib (KO-539) Menin inhibitor | MEN1 | Phase 3 | Acute Myeloid Leukemia (AML); AML; Advanced Malignant Neoplasm; Gastrointestinal Stromal Tumor (GIST) … | Dec 2026 |
| Darlifarnib Farnesyltransferase inhibitor | FNTA | Phase 1 | Solid Tumors With HRAS Alterations | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06001788 | Ziftomenib (KO-539) | Phase 1 | AML | Oncology | Dec 2026 |
| NCT07411586 | Ziftomenib (KO-539) | Phase 1 | Acute Myeloid Leukemia | Oncology | Jan 2027 |
| NCT06026410 | Darlifarnib | Phase 1 | Solid Tumors With HRAS Alterations | Oncology | Jan 2027 |
| NCT06440135 | Ziftomenib (KO-539) | Phase 1 | Acute Myeloid Leukemia | Oncology | Apr 2027 |
| NCT07355335 | Ziftomenib (KO-539) | Phase 1 | KMT2A-rearranged | Oncology | Jul 2027 |
| NCT06769490 | Ziftomenib (KO-539) | Phase 1 | Acute Myeloid Leukemia | Oncology | Sep 2028 |
| NCT04067336 | Ziftomenib (KO-539) | Phase 1 | Advanced Malignant Neoplasm | Oncology | Oct 2028 |
| NCT06448013 | Ziftomenib (KO-539) | Phase 1 | Acute Myeloid Leukemia | Oncology | Dec 2028 |
| NCT06397027 | Ziftomenib (KO-539) | Phase 1 | Refractory Acute Leukemia | Oncology | Dec 2028 |
| NCT06655246 | Ziftomenib (KO-539) | Phase 1 | Gastrointestinal Stromal Tumor (GIST) | Oncology | Jun 2029 |
| NCT05735184 | Ziftomenib (KO-539) | Phase 1 | Acute Myeloid Leukemia | Oncology | Apr 2030 |
| NCT07007312 | Ziftomenib (KO-539) | Phase 3 | Acute Myeloid Leukemia (AML) | Oncology | Nov 2031 |
| NCT06376162 | Ziftomenib (KO-539) | Phase 1 | Relapsed/Refractory KMT2A-r Acute Leukemia | Oncology | Mar 2033 |
Cash and short-term investments of $519m on 2026-06-30; operating cash outflow about $301m a year; runway about 21 months at that burn, to Mar 2028; 0 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 3 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Biomea Fusion Syndax Pharmaceuticals Johnson & Johnson (Janssen) Sumitomo Pharma America
Lyell Immunopharma ALX Oncology Eikon Therapeutics Arcus Biosciences Immuneering
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.